AAAAAA
Results:
1-16
|
Results: 16
Authors:
Ozdemir, V
Kalow, W
Okey, AB
Lam, MSM
Albers, LJ
Reist, C
Fourie, J
Posner, P
Collins, EJ
Roy, R
Citation: V. Ozdemir et al., Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C -> A polymorphism in intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine, J CL PSYCH, 21(6), 2001, pp. 603-607
Authors:
Ozdemir, V
Kalow, W
Posner, P
Collins, EJ
Kennedy, JL
Tang, BK
Albers, LJ
Reist, C
Roy, R
Walkes, W
Afra, P
Citation: V. Ozdemir et al., CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia, J CL PSYCH, 21(4), 2001, pp. 398-407
Authors:
Ozdemir, V
Shear, NH
Kalow, W
Citation: V. Ozdemir et al., What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?, DRUG SAFETY, 24(2), 2001, pp. 75-85
Authors:
Kalow, W
Citation: W. Kalow, Pharmacogenetics in perspective, DRUG META D, 29(4), 2001, pp. 468-470
Authors:
Sy, SKB
Tang, BK
Pastrakuljic, A
Roberts, EA
Kalow, W
Citation: Skb. Sy et al., Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine, EUR J CL PH, 57(5), 2001, pp. 377-386
Authors:
Kalow, W
Citation: W. Kalow, Pharmacogenetics, pharmacogenomics, and pharmacobiology, CLIN PHARM, 70(1), 2001, pp. 1-4
Authors:
Kalow, W
Citation: W. Kalow, Perspectives in pharmacogenetics, ARCH PATH L, 125(1), 2001, pp. 77-80
Authors:
Kalow, W
Citation: W. Kalow, Genetic factors that cause variability in human drug metabolism, INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 1-14
Authors:
Bertilsson, L
Kalow, W
Citation: L. Bertilsson et W. Kalow, Interethnic differences in drug disposition and effects, INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 15-74
Authors:
Basile, VS
Ozdemir, V
Masellis, M
Walker, ML
Heltzer, HY
Lieberman, JA
Potkin, SG
Alva, G
Kalow, W
Macciardi, FM
Kennedy, JL
Citation: Vs. Basile et al., A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, MOL PSYCHI, 5(4), 2000, pp. 410-417
Authors:
Ozdemir, V
Kalow, W
Tang, BK
Paterson, AD
Walker, SE
Endrenyi, L
Kashuba, ADM
Citation: V. Ozdemir et al., Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, PHARMACOGEN, 10(5), 2000, pp. 373-388
Authors:
Kalow, W
Citation: W. Kalow, Pharmacogenetics and evolution, PHARMACOGEN, 10(1), 2000, pp. 1-3
Authors:
Kalow, W
Citation: W. Kalow, Pharmacogenetic research: a revolutionary science, J PSYCH NEU, 24(2), 1999, pp. 139-140
Authors:
Ozdemir, V
Tyndale, RF
Reed, K
Herrmann, N
Sellers, EM
Kalow, W
Naranjo, CA
Citation: V. Ozdemir et al., Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers, J CL PSYCH, 19(5), 1999, pp. 472-475
Authors:
Kalow, W
Endrenyi, L
Tang, BK
Citation: W. Kalow et al., Repeat administration of drugs as a means to assess the genetic component in pharmacological variability, PHARMACOL, 58(6), 1999, pp. 281-284
Authors:
Kalow, W
Ozdemir, V
Tang, BK
Tothfalusi, L
Endrenyi, L
Citation: W. Kalow et al., The science of pharmacological variability: An essay, CLIN PHARM, 66(5), 1999, pp. 445-447
Risultati:
1-16
|